Polypharmacy in schizophrenia
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Although most guidelines recommend monotherapy in schizophrenia, the combined application of multiple psychotropic agents is very common, especially in treatment-refractory cases. We review the empirical basis supporting these attempts and their relevance for clinical practice. RECENT FINDINGS: Polypharmacy intends to address different aspects of treatment resistance, most importantly insufficient response of psychotic positive and negative symptoms, but also cognitive disturbances, affective comorbidity, obsessive-compulsive syndromes and side-effects of antipsychotic drugs. This review summarizes the current state of evidence of combined antipsychotic treatment strategies and the augmentation of antipsychotics with mood stabilizers, antidepressants and experimental substances. SUMMARY: In general, rigorous data on combination therapy in schizophrenia are rare and further randomized controlled trials, naturalistic trials and head-to-head-trials are necessary. Some evidence supports a combination of antipsychotics and antidepressants for negative symptoms and comorbid major depressive episodes. The add-on of lithium and mood stabilizers lacks compelling evidence, but might be beneficial for specific subgroups. For treatment-resistant cognitive symptoms, antipsychotic medication should be combined with cognitive remediation, as no pharmacological add-on strategy has gained convincing evidence so far. Treatment-emergent positive and/or negative symptoms under clozapine monotherapy might benefit from adding a second atypical substance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Intermediate phenotypes and genetic mechanisms of psychiatric disorders
Meyer-Lindenberg, A., & Weinberger, D. R. (2006) · Nature reviews. Neuroscience · doi:10.1038/nrn1993 · Cited by 1,216
Self-citationThe MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010043 · Cited by 744
van Os, J., Rutten, B. P., & Poulton, R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn117 · Cited by 713
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652
Self-citationBerk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype
Meyer-Lindenberg, A., Kohn, P. D., Kolachana, B., Kippenhan, S., McInerney-Leo, A., Nussbaum, R., Weinberger, D. R., & Berman, K. F. (2005) · Nature Neuroscience · doi:10.1038/nn1438 · Cited by 428
Self-citationClozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Metacognitive training for schizophrenia: A multicentre randomised controlled trial
Briki, M., Monnin, J., Haffen, E., Sechter, D., Favrod, J., Netillard, C., Cheraitia, E., Marin, K., Govyadovskaya, S., Tio, G., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.005 · Cited by 65
Metadata
- Authors
- Zink, M., Englisch, S., & Meyer-Lindenberg, A.
- Venue
- Current Opinion in Psychiatry
- Published
- 2010-03
- Volume
- 23
- Issue
- 2
- Pages
- 103-111
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2066616619
- Cited by
- 141
- References
- 14
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polypharmacy in schizophrenia. https://app.cochat.ai/papers/10.1097/yco.0b013e3283366427
- The paper
- Zink, M., Englisch, S., & Meyer-Lindenberg, A. (2010). Polypharmacy in schizophrenia. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e3283366427
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.